An augmented estimation procedure for EHR-based association studies accounting for differential misclassification
ConclusionsThe proposed estimator can effectively combine an error-prone phenotype with gold-standard data from a limited chart review in order to improve analyses of risk factors using EHR data.
ConclusionDirect-to-implant IBR after skin-sparing mastectomy is a viable option for breast cancer patients undergoing neoadjuvant chemotherapy.ResumenIntroducciónLa reconstrucción inmediata (RMI) tras mastectomía en pacientes que han recibido quimioterapia neoadyuvante (QTNA) sigue siendo controvertida. El objetivo de este estudio es analizar y comparar resultados oncológicos y las tasas de complicaciones y reintervención en pacientes sometidas a QTNA y un grupo control.MétodosAnálisis observacional retrospectivo de casos-controles. Pacientes con cáncer de mama inter...
Condition: Breast Cancer Interventions: Drug: GDC-0077; Drug: Placebo; Drug: Palbociclib; Drug: Fulvestrant Sponsor: Hoffmann-La Roche Not yet recruiting
Condition: Breast Cancer Interventions: Drug: SAR439859; Drug: letrozole Sponsor: Sanofi Recruiting
Condition: Triple Negative Breast Neoplasms Interventions: Biological: Pembrolizumab; Drug: Olaparib; Drug: Carboplatin; Drug: Gemcitabine Sponsor: Merck Sharp & Dohme Corp. Not yet recruiting
Condition: Breast Cancer Intervention: Other: FR-Mask Sponsor: China Medical University Hospital Recruiting
Conditions: Breast Neoplasm Female; Symptom Cluster; Tai ji Interventions: Other: wait list control; Behavioral: tai chi group Sponsors: Charles Darwin University; The Affiliated Hospital Of Southwest Medical University; The Affiliated Hospital of Putian University; Shenzhen Sixth People's Hospital Not yet recruiting
Conditions: Anatomic Stage IV Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8 Interventions: Biological: Pembrolizumab; Drug: Tamoxifen; Drug: Vorinostat Sponsors: University of California, San Francisco; Merck Sharp & Dohme Corp. Not yet recruiting
Triple negative breast cancer is the hardest form to treat and most fatal version of the disease. Mt Sinai researchers discovered a protein that May fuel the cancer and a drug to stop it in animals.
Immunotherapy, Ahead of Print.
This study was undertaken to investigate the antibone-metastatic activities and mechanisms of WSZG extract by evaluating the effect of this formula on the cross-talk between bone marrow-derived mesenchymal stem cells (BMSCs) and breast cancer cells in triggering epithelial-mesenchymal transition (EMT) in vivo and in vitro. The results demonstrated that BMSCs might enhance the invasive and metastatic potentials of breast cancer cells as a consequence of EMT induction through direct cell-to-cell contact. WSZG treatment remarkably suppressed motility, invasion, EMT-related gene, and protein markers in BMSC-conditioned breast ...